In last trading session, Cognition Therapeutics Inc (NASDAQ:CGTX) saw 1.35 million shares changing hands with its beta currently measuring 1.00. Company’s recent per share price level of $0.44 trading at $0.06 or 15.25% at ring of the bell on the day assigns it a market valuation of $27.36M. That closing price of CGTX’s stock is at a discount of -570.45% from its 52-week high price of $2.95 and is indicating a premium of 29.55% from its 52-week low price of $0.31. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.41 million shares which gives us an average trading volume of 1.37 million if we extend that period to 3-months.
For Cognition Therapeutics Inc (CGTX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Cognition Therapeutics Inc (NASDAQ:CGTX) trade information
Upright in the green during last session for gaining 15.25%, in the last five days CGTX remained trading in the green while hitting it’s week-highest on Thursday, 04/24/25 when the stock touched $0.44 price level, adding 2.2% to its value on the day. Cognition Therapeutics Inc’s shares saw a change of -37.06% in year-to-date performance and have moved 18.27% in past 5-day. Cognition Therapeutics Inc (NASDAQ:CGTX) showed a performance of -3.90% in past 30-days. Number of shares sold short was 1.54 million shares which calculate 2.33 days to cover the short interests.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -16.44% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 52.79% while estimates for its earnings growth in next 5 years are of 26.97%.
Cognition Therapeutics Inc (NASDAQ:CGTX)’s Major holders
Insiders are in possession of 2.24% of company’s total shares while institution are holding 17.91 percent of that, with stock having share float percentage of 18.32%. Investors also watch the number of corporate investors in a company very closely, which is 17.91% institutions for Cognition Therapeutics Inc that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at CGTX for having 1.15 million shares of worth $1.9 million. And as of 2024-06-30, it was holding 2.8644 of the company’s outstanding shares.
The second largest institutional holder is AWM INVESTMENT COMPANY, INC., which was holding about 0.65 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.6224 of outstanding shares, having a total worth of $1.08 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.01 shares of worth $0.45 million or 1.63% of the total outstanding shares. The later fund manager was in possession of 200.58 shares on Dec 31, 2024 , making its stake of worth around $88534.0 in the company or a holder of 0.32% of company’s stock.
